Autobio Diagnostics Co Ltd
SSE:603658

Watchlist Manager
Autobio Diagnostics Co Ltd Logo
Autobio Diagnostics Co Ltd
SSE:603658
Watchlist
Price: 40.81 CNY -1.07% Market Closed
Market Cap: 23.7B CNY
Have any thoughts about
Autobio Diagnostics Co Ltd?
Write Note

Autobio Diagnostics Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autobio Diagnostics Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Autobio Diagnostics Co Ltd
SSE:603658
Total Current Assets
ÂĄ5.9B
CAGR 3-Years
4%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Total Current Assets
ÂĄ19.5B
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
Total Current Assets
ÂĄ1B
CAGR 3-Years
-4%
CAGR 5-Years
23%
CAGR 10-Years
N/A
S
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
Total Current Assets
ÂĄ6B
CAGR 3-Years
23%
CAGR 5-Years
15%
CAGR 10-Years
14%
Winner Medical Co Ltd
SZSE:300888
Total Current Assets
ÂĄ10.6B
CAGR 3-Years
-1%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Total Current Assets
ÂĄ5.1B
CAGR 3-Years
7%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Autobio Diagnostics Co Ltd
Glance View

Market Cap
23.8B CNY
Industry
Health Care

Autobio Diagnostics Co., Ltd. is a company that has carved a distinctive niche in the biotechnology landscape, particularly within the realm of in-vitro diagnostics (IVD). The company's journey began with a mission to enhance healthcare by providing advanced diagnostic tools that offer precise and timely results. Specializing in the development, production, and distribution of diagnostic reagents and instruments, Autobio has dedicated itself to innovation and quality in medical diagnostics. Its expansive product portfolio covers areas such as immunoassay detection, microbiology, clinical chemistry, and molecular diagnostics, catering to both hospital laboratories and independent labs. The firm prides itself on adopting cutting-edge technology to create solutions that are not only efficient and cost-effective but also align with global health standards. The financial heartbeat of Autobio lies in its strategic approach to generating revenue through diverse streams. With a keen focus on research and development, the company continually innovates its product lines, thereby sustaining a competitive edge in the fast-evolving diagnostics market. Additionally, its revenue model capitalizes heavily on the consumables-market; reagents and test kits are used in routine diagnostics, creating a recurring income source as these products need constant replenishment. By expanding its geographic footprint through partnerships and direct sales channels, Autobio enhances its market reach, strengthening its ability to leverage scale economies. Moreover, the company’s commitment to maintaining strong customer relationships through robust after-sales service and technical support has built a loyal base, further fueling its revenue engine.

Intrinsic Value
75.56 CNY
Undervaluation 46%
Intrinsic Value
Price

See Also

What is Autobio Diagnostics Co Ltd's Total Current Assets?
Total Current Assets
5.9B CNY

Based on the financial report for Sep 30, 2024, Autobio Diagnostics Co Ltd's Total Current Assets amounts to 5.9B CNY.

What is Autobio Diagnostics Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
26%

Over the last year, the Total Current Assets growth was -7%. The average annual Total Current Assets growth rates for Autobio Diagnostics Co Ltd have been 4% over the past three years , 26% over the past five years .

Back to Top